About: SGLT2 inhibitor

An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Class of pharmaceutical drugs

Property	Value
dbo:description	class of pharmaceutical drugs (en) läkemedelsgrupp (sv) فئة من الأدوية تُخفِّض سُكَّر الدم (ar) classe de medicaments glicosúrics (ca) razred farmacevtskih učinkovin (sl) ネフロンの本質的な生理機能を変化させる薬剤 (ja) 나트륨-포도당 공동수송체 2를 억제하는 당뇨병약 (ko) תרופות לטיפול בסוכרת (iw)
dbo:thumbnail	wiki-commons:Special:FilePath/Mechanism_of_action_.png?width=300
dbo:wikiPageExternalLink	https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-interim-clinical-trial-results-find-increased-risk-leg-and-foot https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes
dbo:wikiPageInterLanguageLink	dbpedia-ca:Gliflozina
dbo:wikiPageWikiLink	dbr:Blood_pressure dbr:Electronegativity dbr:Aglycone dbr:Cytochrome_P450 dbr:Dapagliflozin dbr:Diphenylmethane dbr:Phlorizin dbr:Pioglitazone dbr:Chlorine dbr:Sodium dbr:Sanofi dbr:Sodium-glucose_transport_proteins dbr:Insulin dbr:Kidney dbr:Myocardial_infarction dbr:Astellas_Pharma dbr:European_Medicines_Agency dbr:Type_1_diabetes dbr:Diabetes dbr:Atherosclerosis dbr:Body_mass_index dbr:Cardiovascular_disease dbr:Diabetes_medication dbr:Halogen dbr:Hypoglycemia dbr:Obesity dbr:Stroke dbr:Clinical_trial dbr:Boehringer_Ingelheim dbr:Heart_failure dbr:Nephron dbr:Hypotension dbr:Ketone dbr:Biological_half-life dbr:Diabetic_ketoacidosis dbr:Remogliflozin_etabonate dbr:Homeostasis dbr:Hyperglycemia dbr:Electron_density dbr:Cardioprotection dbr:Dehydration dbr:Urinary_tract_infection dbr:Chronic_kidney_disease dbr:Bioavailability dbr:Beta_cell dbr:Empagliflozin dbr:Antioxidant dbr:Anti-inflammatory dbr:Food_and_Drug_Administration dbr:American_Diabetes_Association dbr:Lipolysis dbr:Acute_kidney_injury dbr:Glimepiride dbr:Sitagliptin dbr:Glycosuria dbr:Sergliflozin_etabonate dbr:Adverse_effect dbr:Gluconeogenesis dbr:Neoplasm dbr:Ipragliflozin dbc:Anti-diabetic_drugs dbr:Mechanism_of_action dbr:Canagliflozin dbr:Tofogliflozin dbr:Fournier_gangrene dbr:Kowa_(company) dbr:Reabsorption dbr:Ketogenesis dbr:Systematic_review dbr:Ertugliflozin dbr:Luseogliflozin dbr:Sotagliflozin dbr:FDA_Adverse_Event_Reporting_System dbr:Cmax_(pharmacology) dbr:Sirtuin_1 dbr:Proximal_convoluted_tubule dbc:SGLT2_inhibitors dbr:Major_adverse_cardiovascular_events dbr:PPARGC1A dbr:Aromatic dbr:Renal_glucose_reabsorption dbr:Mycosis dbr:Epithelial_cells dbr:DPP-4_inhibitors dbr:SLC5A1 dbr:Intestinal_mucosa dbr:FDA dbr:Glucagon-like_peptide-1_receptor_agonist dbr:FGF21 dbr:Blood_sugar dbr:Diuretics dbr:Network_meta-analysis dbr:Protein_binding dbr:Type_II_diabetes dbr:Body_weight dbr:Limb_amputation dbr:Anomeric dbr:Antidiabetic_drugs dbr:Elimination_half-life dbr:Endothelial_cells dbr:Loop_diuretics dbr:Dose-dependent dbr:Glomerular_filtration dbr:Glucosuria dbr:Glycemic_control dbr:Osmotic_diuresis dbr:Pharmacokinetic dbr:Pharmacokinetic_profile dbr:Renal_excretion dbr:Type_II_diabetes_mellitus dbr:Kidney_function dbr:Sodium-glucose_transport_protein_2 dbr:Thiazides dbr:Structure-activity_relationship dbr:File:Phlorhizin.svg dbr:File:Canagliflozin.svg dbr:File:Dapagliflozin_structure.svg dbr:File:Empagliflozin.svg dbr:File:Mechanism_of_action_.png
dbp:displayAuthors	6 (xsd:integer)
dbp:nameListStyle	vanc (en)
dbp:wikiPageUsesTemplate	dbt:Sodium-glucose_transporter_modulators dbt:Oral_hypoglycemics dbt:As_of dbt:Authority_control dbt:Citation_needed dbt:Cite_web dbt:Cs1_config dbt:Main dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates
dct:subject	dbc:Anti-diabetic_drugs dbc:SGLT2_inhibitors
rdf:type	owl:Thing
rdfs:label	SGLT2 inhibitor (en) Gliflozina (ca) مثبطات إس جي إل تي 2 (ar) SGLT-2-Hemmer (de) Gliflozina (es) Gliflozine (fr) SGLT2阻害薬 (ja) Gliflozine (it) Глифлозины (ингибиторы SGLT2) (ru) 钠-葡萄糖协同转运蛋白2抑制剂 (zh)
owl:sameAs	dbpedia-ca:SGLT2 inhibitor wikidata:SGLT2 inhibitor dbpedia-de:SGLT2 inhibitor dbpedia-es:SGLT2 inhibitor dbpedia-it:SGLT2 inhibitor dbpedia-tr:SGLT2 inhibitor dbpedia-fr:SGLT2 inhibitor dbpedia-he:SGLT2 inhibitor dbpedia-ja:SGLT2 inhibitor dbpedia-ru:SGLT2 inhibitor dbpedia-zh:SGLT2 inhibitor dbpedia-ar:SGLT2 inhibitor dbpedia-fi:SGLT2 inhibitor dbpedia-la:SGLT2 inhibitor dbpedia-mk:SGLT2 inhibitor dbpedia-global:SGLT2 inhibitor
prov:wasDerivedFrom	wikipedia-en:SGLT2_inhibitor?oldid=1310286837&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Phlorhizin.svg wiki-commons:Special:FilePath/Empagliflozin.svg wiki-commons:Special:FilePath/Canagliflozin.svg wiki-commons:Special:FilePath/Dapagliflozin_structure.svg wiki-commons:Special:FilePath/Mechanism_of_action_.png
foaf:homepage	http://U.S. http://U.S.
foaf:isPrimaryTopicOf	wikipedia-en:SGLT2_inhibitor
is dbo:class of	dbr:Dapagliflozin dbr:Empagliflozin dbr:Canagliflozin dbr:Sotagliflozin
is dbo:wikiPageRedirects of	dbr:SGLT-2_inhibitor dbr:SGLT-2_inhibitor dbr:Sodium-glucose_cotransporter-2_inhibitors dbr:Sodium-glucose_cotransporter-2_inhibitors dbr:Gliflozin dbr:Flozins dbr:Gliflozins dbr:Sodium-glucose_co-transporter-2_inhibitor dbr:Sodium_glucose_transporter_(SGLT2)_inhibitors dbr:SGLT2_inhibitors
is dbo:wikiPageWikiLink of	dbr:Dapagliflozin dbr:Type_2_diabetes dbr:Type_1_diabetes dbr:Diabetes dbr:Metformin dbr:Heart_failure dbr:Diabetic_ketoacidosis dbr:Empagliflozin/metformin dbr:Dapagliflozin/metformin dbr:Empagliflozin/linagliptin/metformin dbr:Canagliflozin/metformin dbr:Diabetic_nephropathy dbr:Ketoacidosis dbr:Ketosis dbr:COVID-19_drug_development dbr:PDE5_inhibitor dbr:Canagliflozin dbr:Fournier_gangrene dbr:Empagliflozin/linagliptin dbr:Ketolysis dbr:Luseogliflozin dbr:SGLT-2_inhibitor dbr:Major_adverse_cardiovascular_events dbr:Sodium/glucose_cotransporter_2 dbr:Glucagon-like_peptide-1_receptor_agonist dbr:Sodium-glucose_cotransporter-2_inhibitors dbr:Gliflozin dbr:Flozins dbr:Gliflozins dbr:Sodium-glucose_co-transporter-2_inhibitor dbr:Sodium_glucose_transporter_(SGLT2)_inhibitors dbr:SGLT2_inhibitors
is dbp:class of	dbr:Dapagliflozin dbr:Dapagliflozin/saxagliptin dbr:Dapagliflozin/saxagliptin/metformin dbr:Empagliflozin dbr:Empagliflozin/metformin dbr:Dapagliflozin/metformin dbr:Empagliflozin/linagliptin/metformin dbr:Canagliflozin/metformin dbr:Canagliflozin dbr:Empagliflozin/linagliptin dbr:Sotagliflozin dbr:Dapagliflozin/sitagliptin
is foaf:primaryTopic of	wikipedia-en:SGLT2_inhibitor